摘要
目的:研究苦参素联合恩替卡韦治疗对慢性乙肝患者肝纤维化进程及免疫应答状态的影响。方法:选择2015年3月~2017年6月期间在解放军总医院第一附属医院诊断为慢性乙型病毒性肝炎的患者纳入研究,随机分为接受苦参素联合恩替卡韦治疗的实验组、接受恩替卡韦单药治疗的对照组。治疗前及治疗后3个月、6个月时,测定血清中肝纤维化指标、免疫细胞因子的含量以及外周血中免疫细胞的数目。结果:与组内治疗前相应指标比较,两组患者治疗后3个月、6个月时血清中PC-III、C-IV、TGF-β1、Ang-II、IFN-γ的含量以及外周血中Th1细胞的数目均显著降低,外周血中Th2、mDC、pDC细胞的数目及CD80、CD86的表达强度以及血清中IL-5、IL-10的含量均显著升高;实验组患者治疗后3个月、6个月时血清中PC-III、C-IV、TGF-β1、Ang-II、IFN-γ的含量以及外周血中Th1细胞的数目均显著低于对照组,外周血中Th2、mDC、pDC细胞的数目及CD80、CD86的表达强度以及血清中IL-5、IL-10的含量均显著高于对照组。结论:苦参素联合恩替卡韦治疗慢性乙肝能够延缓肝纤维化进程并改善免疫应答。
Objective:To study the effect of kushenin combined with entecavir therapy on hepatic fibrosis and immune response in patients with chronic hepatitis B.Methods:Patients who were diagnosed with chronic viral hepatitis B in First Affiliated Hospital of PLA General Hospital between March 2015 and June 2017 were enrolled in the study and randomly divided into the experimental group who kushenin combined with entecavir therapy and the control group who received entecavir monotherapy.The levels of hepatic fibrosis indexes and immune cytokines in serum as well as the number of immune cells in peripheral blood were measured before treatment as well as 3 months and 6 months after treatment.Results:Compared with the corresponding indexes of same group before treatment,serum PC-III,C-IV,TGF-β1,Ang-II and IFN-γlevels as well as peripheral blood Th1 cell number of both groups of patients were significantly lower whereas Th2,mDC and pDC cell number as well as CD80 and CD86 expression intensity in peripheral blood as well as IL-5 and IL-10 levels in serum were significantly higher 3 months and 6 months after treatment;serum PC-III,C-IV,TGF-β1,Ang-II and IFN-γlevels as well as peripheral blood Th1 cell number of experimental group 3 months and 6 months after treatment were significantly lower than those of control group whereas Th2,mDC and pDC cell number as well as CD80 and CD86 expression intensity in peripheral blood as well as IL-5 and IL-10 levels in serum were significantly higher than those of control group.Conclusion:kushenin combined with entecavir treatment of chronic hepatitis B can delay hepatic fibrosis progression and improve immune response.
作者
朱睿
ZHU Rui(Digestive System Department,First Affiliated Hospital of PLA General Hospital,Beijing,100048)
出处
《海南医学院学报》
CAS
2018年第11期1069-1072,共4页
Journal of Hainan Medical University
基金
国家自然科学基金青年科学基金项目No.81600476~~